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Purpose. )ere are no known effective medical treatments for refractory MPNST. Inactivation of the NF1 tumor suppressor in
MPNST results in upregulation of mTOR (mammalian target of rapamycin) signaling and angiogenesis, which contributes to
disease progression. We conducted a phase II study for patients (pts) with refractory MPNST combining everolimus (10mg PO
once daily) with bevacizumab (10mg/kg IV every 2weeks) to determine the clinical benefit rate (CBR) (complete response, partial
response (PR), or stable disease (SD)≥ 4months). Patients and Methods. Patients ≥18 years old with chemotherapy refractory
sporadic or NF1 MPNSTwere eligible. Tumor response was assessed after every 2 cycles (the WHO criteria). A two-stage design
targeting a 25% CBR was used: if≥ 1/15 pts in stage 1 responded, enrollment would be expanded by 10 pts, and if≥ 4/25 patients
had clinical benefit, the combination would be considered active. Results. Twenty-five pts, 17 with NF1 and 8 with sporadic
MPNST, enrolled. One of 15 pts in stage 1 had clinical benefit. Of 10 additional pts enrolled, 2 had clinical benefit. )e median
number of completed cycles was 3 (range 1–16). Adverse events were similar to those known for this combination. Conclusion.
With a CBR of 12% (3/25), the combination of everolimus and bevacizumab did not reach the study’s target response rate and is
not considered active in refractory MPNST.
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1. Introduction
Malignant peripheral nerve sheath tumors (MPNST) are
rare and clinically aggressive soft tissue sarcomas that occur
with greater incidence in individuals with neurofibromatosis
type 1 (NF1) [1, 2]. Complete surgical resection is required
for cure. Response to cytotoxic chemotherapy used to treat
other soft tissue sarcomas is poor [3]. To date, no phase II
trials with targeted therapies have resulted in clinical benefit
as demonstrated by tumor shrinkage or improvement in
progression-free survival [4].
In an Nf1/p53-mutant MPNST model, the Cichowski
group identified that the mammalian target of rapamycin
(mTOR) is hyperactive and that the mTOR inhibitor siro-
limus substantially delayed tumor growth [5]. Angiogenesis
contributes to progression of MPNST, and in this mouse
model, development of resistance was associated with re-
vascularization and upregulation of the vascular endothelial
growth factor. )e combination of sunitinib, a multitargeted
kinase inhibitor, which in part, mediates antitumor activity
by inhibition of angiogenesis, with sirolimus resulted in
prolongation of survival compared to treatment with either
agent alone (Cichowski lab, unpublished data).
As angiogenesis appears critical to the development of
resistance to treatment with sirolimus in vivo and the tol-
erability of sunitinib with an mTOR inhibitor raised con-
cerns, we elected to develop a phase II trial combining the
mTOR inhibitor everolimus with the recombinant hu-
manized anti-VEGF monoclonal antibody bevacizumab to
evaluate the clinical activity of this combination in patients
with sporadic or NF1-associated MPNST. At the time of
development of our trial, the tolerable doses and safety of
this combination had been established [6].
2. Materials and Methods
2.1. Patient Population. Eligibility criteria were as follows:
patients aged ≥18 years with histologically confirmed
unresectable, refractory, or metastatic high-grade NF1 or
sporadic MPNST; presence of measurable disease; pro-
gressive disease after ≥1 prior cytotoxic chemotherapy
(unless the patient refused chemotherapy or chemotherapy
was felt not to be in the best interest of the patient by the
treating physician); Eastern Cooperative Oncology Group
(ECOG) performance status of 0 to 2; adequate bone
marrow, liver, and renal function; fasting serum cholesterol
≤300mg/dL and triglycerides ≤2.5x the upper limit of
normal; urine protein creatinine ratio ≤0.5; left ventricular
ejection fraction ≥50% in patients who previously received
an anthracycline; recovery from toxic effects of prior therapy
to ≤grade 1 (CTCAE version 4); a minimum of 3weeks from
prior chemotherapy, 7 days from a biologic agent, 4 weeks
from radiation, and 4weeks from major surgery; willingness
to use birth control, and for patients with NF1, documen-
tation of diagnostic criteria [7]. Key exclusion criteria were
as follows: patients receiving chronic systemic administra-
tion of a corticosteroid or another immunosuppressive
agent; presence of severe or uncontrolled medical condition
that could affect study participation including brain or
leptomeningeal metastases, heart failure, severely impaired
lung function, and active or uncontrolled hepatitis; prior
treatment with an mTOR inhibitor for MPNST or bev-
acizumab; concurrent use of anticoagulant drugs at treat-
ment doses, strong CYP3A4 inhibitors, St. John’s Wort,
grapefruit, or enzyme inducing anticonvulsants.
)is multi-institutional trial was coordinated through the
Sarcoma Alliance for Research through Collaboration
(SARC) and funded by a Department of Defense Clinical Trial
Award W81XWH-10-1-0681. )e trial was IND exempt.
Everolimus was supplied by Novartis and bevacizumab by
Genentech. )e study was conducted after approval from the
Department of Defense Protocol Review, and institutional
review boards from all participating sites and all patients
provided written informed consent before participating. )e
trial was registered with ClinicalTrials.gov (NCT01661283).
2.2. Study Design
2.2.1. Treatment Overview. Everolimus (2.5, 5, and 10mg
tablets) was administered at 10mg per dose once daily at the
same time on a continuous dosing schedule. Bevacizumab
(400mg vials) was administered at 10mg/kg as intravenous
infusion over 30–90minutes every 2weeks (days 1 and 15).
One treatment cycle was 28 days. All patients on study re-
ceived prophylaxis against Pneumocystis jirovecii pneumo-
nia using trimethoprim/sulfamethoxazole or inhaled
pentamidine. Treatment could continue until a maximum of
2 years and until disease progression or unacceptable tox-
icity. Adverse events were graded using CTCAEv4 and at-
tributed to either or both study agents. Detailed guidelines
were provided for the management of drug-related adverse
events such as pneumonitis, hypertension, mucositis, and
proteinuria.
For everolimus-related adverse events, up to 2 dose re-
ductions (from 10mg to 5mg and then to 2.5mg per dose)
were permitted, provided adverse events resolved within
3weeks to ≤grade 1. Everolimus was dose reduced for related
intolerable adverse events including grade 2 pneumonitis and
for grade 3 adverse events (with exception of reversible ele-
vation of alanine aminotransferase (ALT) or aspartate ami-
notransferase (AST), nausea and vomiting less than 3 days, or
grade 3 hyperlipidemia). Everolimus was permanently dis-
continued for related grade 4 adverse events. For bev-
acizumab-related adverse events, no dose reductions were
permitted, and treatment was permanently discontinued for
most grade 3 and all grade 4 related adverse events, and if
bevacizumab treatment was interrupted for ≥8weeks.
2.3. Assessments. History and physical examination in-
cluding vital signs (blood pressure and O2 saturation) and
laboratory studies including complete blood counts with
differential count, fasting glucose, and lipid panel, and
comprehensive chemistry panel (creatinine, blood urea
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nitrogen, albumin, total protein, AST, ALT, total bilirubin,
alkaline phosphatase, and uric acid) were performed prior to
every treatment cycle. Response evaluation (the WHO
criteria) with appropriate imaging studies and evaluation of
cardiac function by echocardiogram were performed before
every other treatment cycle (3, 5, 7, etc.). Peripheral blood
samples were obtained for analysis of VEGF and VEGFR,
S6K1 (p70s6 kinase) activity, eIF4E, eIF2α, and AKT
phosphorylation at baseline and prior to cycles 3 and 5.
2.4. StatisticalMethods. A two-stage SimonMinimax phase
II design was used to determine the clinical benefit
rate(CBR) (number of patients experiencing a complete
response (CR), a partial response (PR), or stable disease
(SD) for ≥4months). Confirmation of responses was re-
quired. )e target clinical benefit rate was 25%, and a
clinical benefit rate <5% would be considered un-
interesting. Fifteen patients were to enroll on the first stage,
and if ≥1 of 15 patients experienced clinical benefit, en-
rollment would expand to a total of 25 patients. With
clinical benefit in ≥4/25 patients, everolimus in combi-
nation with bevacizumab would be considered active in
that it would be consistent with a 25% clinical benefit rate.
Assuming the number of successes is binomially distrib-
uted, this design has a one-sided alpha of 5.0% and a power
of 90% for detecting a true success probability of at least
25% versus the null hypothesis success rate of 5% or less.
Pharmacodynamic endpoints were summarized with de-
scriptive statistics.
3. Results
3.1.EnrollmentCharacteristics. Twenty-five eligible patients
enrolled on the trial: 15 enrolled on the first stage and 10 on
the second stage. Characteristics of all patients and sep-
arately for patients with NF1 (N � 17) and with sporadic
(N � 8) MPNST are listed in Table 1. Patients with NF1
MPNST were younger (median age 28 (range, 19, 63)
years) than patients with sporadic MPNST (median age 61
(range, 19, 81) years). More females than males enrolled.
)e most frequent primary tumor location was in the
extremities, and only 1 tumor involved the face (parotid
gland). While the majority of the primary tumors were
initially resected, approximately half had microscopic or
macroscopic positive margins and 15 of 20 initially
resected tumors recurred locally. At the initial diagnosis,
only 14% of patients had metastatic disease, but at en-
rollment on this trial, 90% had metastatic disease. )e
majority of patients (92%) had received cytotoxic che-
motherapy prior to enrollment (median number of regi-
mens 2, range 0–5), and 84% of patients had received prior
radiation therapy. Ninety-two percent of patients had a
baseline ECOG of 0 or 1.
3.2. Response Evaluation. )is study used the WHO criteria
[8] to evaluate the response, given that most MPNST are
not spherical. Of 15 patients enrolled on the first stage, 1
patient had clinical benefit with SD at the 4-month
evaluation (Table 2). )is patient had a sporadic MPNST
and experienced progressive disease at the post-cycle 6
evaluation. One additional patient had a partial response at
the pre-cycle 3 evaluation, which was not confirmed at
subsequent restaging. Given that 1 patient had experienced
clinical benefit, an additional 10 patients were enrolled on
the second stage, of whom 2 experienced clinical benefit
with SD as best response. Both patients had NF1 MPNST;
one experienced grade 5 intraabdominal hemorrhage
during cycle 7, considered possibly related to bevacizumab,
and the other patient had stable disease for 16 cycles when
disease progressed.)emedian cycle number in all patients
was 3 (range 1–16). )us, with a total of 3/25 patients with
clinical benefit, the target clinical benefit rate was not
reached and the combination of everolimus and bev-
acizumab was considered inactive. In addition to evalu-
ating response by the WHO, as a secondary objective, we
compared the WHO response to RECIST response (Ta-
ble 2). Using RECIST, in the first stage, the best response
was clinical benefit with SD in 2 patients, and in the second
stage, the best response was clinical benefit with SD in 4
patients. )us, had our study used RECIST criteria, the
desired clinical benefit rate would have been 6/25 patients
and the target response rate would have been reached. )e
waterfall plots (Figures 1(a) and 1(b)) for the WHO and
RECIST best response shows that response trends were
similar with a substantial number of tumors being stable,
followed by tumors clearly growing and one tumor with
clear tumor shrinkage.
3.3. Adverse Events. )e combination of everolimus and
bevacizumab was tolerated with adverse events similar to
those known for this combination (supplemental Table 1 for
all adverse events and all drug-related adverse events). Most
adverse events were grade 1 or 2. )e most frequent drug-
related adverse events were oral mucositis, nausea, vomiting,
fatigue, weight loss, anorexia, and hypertension. Grade 3
drug-related adverse events which occurred in more than 1
patient were mucositis (n� 5), ALT elevation (n� 3),
hypophosphatemia (n� 3), and fatigue (n� 2). Everolimus
was dose reduced in 4 patients for grade 1–3 adverse events.
Everolimus and bevacizumab treatment were discontinued
permanently in 7 patients who experienced grade 1–5 ad-
verse events, not all of which were considered related to
study drugs (Table 3).
Reasons for discontinuation of therapy were disease
progression (N� 19), adverse events (n� 4), initiation of
systemic treatment with dexamethasone, which was pro-
hibited as concomitant medication (n� 1), and physician
decision (n� 1).
3.4. Pharmacodynamic Endpoints. Samples for analysis of
VEGF and VEGFR were collected for 23 patients at baseline,
14 patients at the time of the first restaging, and 8 patients at
the time of the second restaging. In patients with paired
samples, VEGF on treatment increased and VEGFR2 de-
creased compared to baseline (Figures 1(c) and 1(d)).
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4. Discussion
)is phase II trial was directed at patients with refractory
NF1 or sporadic MPNST. Patients enrolled indeed had
refractory disease; the majority had prior surgery, chemo-
therapy, and radiation therapy. While, based on the liter-
ature, approximately 50% of MPNST occur in individuals
with NF1 [1], this trial enrolled more NF1 MPNST (N� 17)
compared to sporadic MPNST (N� 8). As reported pre-
viously, patients with NF1 MPNST were younger (median
age 28 years) compared with sporadic MPNST (median age
61 years), consistent with NF1 being a tumor suppressor [9].
MPNST in NF1 frequently develop in preexisting neurofi-
bromas, which may make surgical removal of MPNSTmore
difficult [1, 4]. However, the majority of NF1 and sporadic
MPNSTwere resected, and the incidence of microscopic and
macroscopic positive margins was similar in sporadic and
NF1 MPNST. Many tumors recurred locally, and at the time
of enrollment, most patients had metastatic and disease
underlying the aggressive clinical behavior of MPNST.
Table 1: Patients’ baseline characteristics.
Characteristic All (N� 25) NF1 MPNST (N� 17) Sporadic MPNST (N� 8)
Median age at diagnosis, years (range) 37 (19, 81) 28 (19, 63) 61 (19, 81)
Female, n (%) 15 (60) 10 (58.8) 5 (62.5)
Asian, n (%) 1 (4) 1 (5.9) 0 (0)
Black or African American, n (%) 8 (32) 5 (29.4) 3 (37.5)
White, n (%) 16 (64) 11 (64.7) 5 (62.5)
Primary tumor location, n (%)
Extremities 10 (40) 7 (41.3) 3 (37.5)
Trunk
Chest wall 3 (12) 3 (17.6) 0 (0)
Spine 2 (8) 2 (11.8) 0 (0)
Mediastinal soft tissue 1 (4) 1 (5.9) 0 (0)
Pelvis 2 (8) 2 (11.8) 0 (0)
Retroperitoneum 1 (4) 0 (0) 1 (12.5)
Abdominal wall 1 (4) 1 (5.9) 0 (0)
Axilla 2 (8) 1 (5.9) 1 (12.5)
Parotid gland 1 (4) 0 (0) 1 (12.5)
Primary tumor resected, n (%) 20 (80) 13 (76.5) 7 (87.5)
Margins of surgical resection, n (%)
R0: microscopic negative 9 (45) 7 (53.8) 2 (28.6)
R1: microscopic positive 4 (20) 2 (15.4) 2 (28.6)
R2: gross residual disease 5 (25) 3 (23.1) 2 (28.6)
If resected, did the primary tumor locally recur, n (%) N� 20 N� 13 N� 7
No 5 (25) 2 (15.4) 3 (42.9)
Yes 15 (75) 11 (84.6) 4 (57.1)
Metastatic disease at diagnosis, n (%) N� 21 N� 13 N� 8
No 18 (86) 12 (92.3) 6 (75)
Yes 3 (14) 1 (7.7) 2 (25)
Metastatic disease at enrollment, n (%) N� 21 N� 13 N� 8
No 2 (10) 1 (7.7) 1 (12.5)
Prior chemotherapy, n (%)
No 2 (8) 2 (11.8) 0 (0)
Yes 23 (92) 15 (88.2) 8 (100)
No. of prior treatment regimens
Median (range) 2 (0, 5) 2 (0, 5) 2 (1, 4)
Patient had prior radiation, N (%)
No 4 (16) 3 (17.6) 1 (12.5)
Yes 21 (84) 14 (82.4) 7 (87.5)
No. of prior radiation treatments
Median (range) 1 (0, 3) 1 (0, 3) 1 (0, 2)
Patient had prior surgeries, N (%)
No 2 (8) 1 (5.9) 1 (12.5)
Yes 23 (92) 16 (94.1) 7 (87.5)
No. of prior surgeries
Median (range) 2 (0, 8) 2 (0, 8) 2 (0, 5)
ECOG at baseline, N (%)
0 12 (48) 8 (47.1) 4 (50)
1 11 (44) 7 (41.2) 4 (50)

















































































Table 2: Tumor response evaluation based on the WHO and RECIST criteria (stage 1: 15 patients; stage 2: 10 patients).
Response evaluation
Stage 1 Stage 2
Cycle 2 (N 15) Cycle 4 (N 8) Cycle 2 (N 10) Cycle 4 (N 5)
WHO
Partial response 1∗ 0 0 0
Stable disease 7 1 5 2
Progressive disease 5 5 4 3
Others 2 2 1 0
RECIST
Partial response 0 0 0 0
Stable disease 9 2 5 4
Progressive disease 4 4 4 1
Others 2 2 1 0
∗Partial response was unconrmed and thus not counted as clinical benet.
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e goal of our study was to evaluate whether the
combination of the mTOR inhibitor everolimus with the
angiogenesis inhibitor bevacizumab would result in a
modest clinical benet rate, which included conrmed
partial and complete responses and disease stability for four
or more treatment cycles. Our study used the WHO criteria
[8] to assess the response, given that most MPNST are
nonspherical. In stage 1 and 2 combined, 3/25 patients
experienced clinical benet, all with SD as best response.
One of these patients had extended stable disease for over
1 year, which is remarkable for MPNST, most of which are
known to progress rapidly. In addition, one patient in the
initial stage had a PR at the time of rst restaging; however,
at the time of restaging after 4 cycles, the patient had PD and
this was not counted as a success. us, our study did not
reach the desired CBR of ≥4/25 and the combination of
everolimus and bevacizumab is considered inactive. e
WHO criteria dene the growth of any target lesion by ≥25%
as PD [8].is is in contrast to RECISTwhere the sum of the
longest diameters of the target lesions is used to determine
progression [10]. When we applied RECIST criteria to our
study, 6/25 patients would have met the criteria for clinical
benet. Irrespective of the response criteria selected, only a
small proportion of patients experienced meaningful disease
stabilization. Similar to results in the NF1 MPNST mouse
model, we did not observe tumor shrinkage in our trial [5].
In the NF1 mouse model, sirolimus nearly doubled survival.
We used duration of SD as an indicator for benet, and in
that light, it may be helpful to reconsider the utility of
RECIST versus WHO criteria. e selection of the WHO
over RECIST criteria may be most meaningful in upfront
trials for the more precise measurement of primary tumors.
In the setting of refractory disease where most patients have
metastases, which are less complex, the selection of the
WHO over RECIST criteria may not provide an advantage.
Standardized criteria in future clinical trials which allow for
a meaningful comparison of response and disease stability
and comparison to mouse preclinical studies will be helpful
[11]. In addition, careful comparisons of trial design,































Figure 1: Waterfall plots for best response by the WHO (a) and RECIST (b) and changes in plasma VEGF (c) and VEGFR2 (d) in patients
with paired samples at baseline and prior to cycles 3 (N 13) and 5 (N 8).
Table 3: Adverse events resulting in dose reduction (DR) or discontinuation (DC) of therapy.
Adverse events N Grade
Attribution Intervention
Everolimus Bevacizumab Everolimus Bevacizumab
Abdomen hemorrhage 1 5 − + DC DC
Alanine aminotransferase 1 3 + − DC DC
Proteinuria 1 2 − + DC DC
Proteinuria∗ 1 1 − + DC DC
Neurologic decline∗ 1 3 − − DC DC
Back pain 1 2 − − DC DC
Pain∗ 1 4 − − DC DC
romboembolism 1 3 − − None DC
Fatigue 1 3 + + DR None
Mucositis 2 2 + − DR None
Mucositis 1 1 + − DR None
Ear pain 1 1 + − DR None
∗O-treatment reason for these patients was disease progression.
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trials will be helpful to determine whether responses achieved
in preclinical studies can be translated to patients [12]. For
example, ideally tumors would be measured using similar
criteria in preclinical and clinical trials. Assuring that drug
exposures are similar in the preclinical and clinical setting
would also be helpful for a more meaningful comparison of
results. In our study, bevacizumab and everolimus were
administered at the single-agent phase II recommended
doses. )e combination of bevacizumab and everolimus was
tolerated with dose reductions of everolimus in 4 patients and
discontinuation of bevacizumab in 3 patients for related
adverse events. Pharmacodynamic studies for bevacizumab in
blood samples were consistent with target inhibition. Due to
lack of activity in our trial and previously documented in-
hibition of targets downstream of mTOR at comparable doses
of everolimus, we did not perform pharmacodynamic ana-
lyses for mTOR inhibition [13, 14]. A limitation of our study
was that tumor biopsies were not collected. Pretreatment and
on-treatment tumor biopsies for genomic and metabolomic
studies will have utility in assessing mechanisms of response
and resistance, thus advancing better therapies for MPNST.
)ese studies are being incorporated in future SARC co-
ordinated trials targeting MPNST, provided biopsies can be
obtained safely. Finally, we believe that combinatorial targeted
treatment approaches will also have applicability to NF1-
related plexiform neurofibromas and atypical neurofibromas.
5. Conclusions
While the combination of everolimus and bevacizumab was
considered inactive, signs of activity were noted in highly
refractory patients. Our study confirmed that histology-
specific phase II trials with targeted agents for MPNST are
feasible and that predefined trial success can be dramatically
altered based on choice of response criteria (the WHO versus
RECIST). Our hope is that as more effective targeted com-
bination therapies, which result in substantial tumor
shrinkage, are discovered in preclinical models, translation to
the clinic will also yield sustained objective tumor regression.
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